1. Introduction {#s0005}
===============

Thyroid cancer is the most common endocrine malignancy with increasing incidence in many parts of the world. The follicular cell-derived thyroid cancer is histologically classified into differentiated thyroid cancer (DTC), poorly differentiated thyroid cancer (PDTC) and anaplastic thyroid cancer (ATC). DTC is further classified to papillary (PTC) and follicular thyroid cancer (FTC). Genes of the mitogen-activated protein kinase (MAPK) signaling (*EGFR*, *Ras*, *BRAF*, *RET*/*PTC*, etc.) and phosphatidylinositol-3 kinase/Akt (PI3K/Akt) signaling (*ALK*, *PIK3CA*, *PTEN*, *AKT1*, etc.) pathways are the most frequently mutated genes in thyroid cancer ([@bb0045; @bb0035]). Aberrant activation of these major signaling pathway genes results in uncontrolled cell division, proliferation, invasion and metastasis. ([@bb0020; @bb0025]). *mTOR* is a serine/threonine kinase that is an important downstream mediator of the PI3K/Akt signaling pathway. The *mTOR* is a key regulator of protein synthesis, cell size and growth, apoptosis, and metabolism in response to nutrients, growth factors and cellular energy. It is frequently deregulated in many types of human cancers ([@bb0005]). Recently, whole exome sequencing of ATC showed 9% (2/22) of somatic point mutations (R164Q and M2327I) in *mTOR* gene ([@bb0015]). An *mTOR* mutation (F2108L) has also recently been found in a whole exome sequencing of a patient with ATC ([@bb0040]). However, to our knowledge, systematic search for *mTOR* mutations in DTC in a large sample using conventional methods has not been undertaken despite the importance of the PI3K/Akt pathway and its component genes which were extensively studied in thyroid cancer ([@bb0020]). We therefore, analyzed the *mTOR* mutations both in benign and follicular cell-derived DTC in a series of patients including a sample with highly aggressive histopathological features from Saudi Arabia.

2. Materials and methods {#s0010}
========================

We initially analyzed 63 thyroid neoplasms that include 10 benign multi nodular goiters and 53 DTC (41 classical papillary thyroid cancer (CPTC), 7 follicular variant (FVPTC), 1 tall cell variant, 1 hurthle cell cancer, 1 columnar cell variant PTC, and 2 PDTC). After obtaining an institutional review board (IRB) approval, the tumor samples were carefully examined by an endocrine pathologist and 10 μm tumor samples were dissected from formalin fixed paraffin embedded tissue. Genomic DNA was extracted using the Gentra Puregene DNA extraction kit (Qiagen, Valencia, CA) according to the manufacturer\'s instruction. The primers were designed to encompass the exon and the exon-intron boundaries ([Table 1](#t0005){ref-type="table"}). Since the *mTOR* gene is large with 58 exons, we choose exons that were previously reported to be frequently mutated in other human cancers (exons 1, 2, 3, 4, 5, 6, 12, 16, 21, 25, 29, 38, 42, 46, 50, 51, 52, and 55) based on the COSMIC (Catalog of Somatic Mutations in Cancer) Database, UK. (<http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/>). The PCR conditions were as follows: initial denaturation at 95 °C for 5 min followed by 35 cycles of denaturation at 95 °C for 1 min, annealing at 59 °C for 45 s, and extension at 72 °C for 45 s. This was followed by a final extension step at 72 °C for 7 min. We amplified the selected exons by polymerase chain reaction (PCR) and directly sequenced the PCR product using the Big Dye terminator v3.1 cycle sequencing ready reaction kit (Applied Biosystems). Identified genetic variants were confirmed in forward and reverse directions. After the completion of screening of the 63 samples for the exons mentioned above and in order to increase the chance of finding mutations, we then extended our search for *mTOR* mutations to 21 selected high grade tumors (large tumors with extra-thyroidal extension and lymph node metastases and/or distant metastases) and limited our search to the most frequently previously described mutated exons (1, 3, 21, 38, 42, 46, and 55). GenBank accession number of *mTOR* gene is [NM_004958.3](ncbi-n:NM_004958.3){#ir0010}.

3. Results {#s0015}
==========

Irrespective of our approach, neither the initial screening of 63 randomly selected thyroid tumors (exons 1, 2, 3, 4, 5, 6, 12, 16, 21, 25, 29, 38, 42, 46, 50, 51, 52, and 55) nor the further search in the 21 high grade thyroid cancer revealed *mTOR* mutations (exons 1, 3, 21, 38, 42, 46, 50, 51, 52 and 55). Nonetheless, as illustrated in [Fig. 1](#f0005){ref-type="fig"}, we found a rare synonymous genetic variant resulting in C \> G transversion (C663G) in 1 out 63 samples (1.6%) and a frequent synonymous variant resulting in C \> T transition (C5333T) in 14 out of 84 samples, (16%). Both of these single nucleotide polymorphisms (SNPs) have been reported (C663G, rs112439072; C5553T, rs2275527) in the SNP databases (<http://www.ncbi.nlm.nih.gov/projects/SNP/>) and (<http://asia.ensembl.org/Homo_sapiens/Transcript/Variation_Transcript/>).

4. Discussion {#s0020}
=============

The *mTOR* and its canonical signaling pathway has been shown to be frequently deregulated in human cancer and has become a major therapeutic target. Point mutations of the *mTOR* gene are expected to play an important role in tumorigenesis and tumor invasion as it has been recently demonstrated that artificially induced mutations of conserved amino acids in *mTOR* exhibit gain-of-function and oncogenic potential both in vitro and in vivo ([@bb0030]). Furthermore, natural somatic *mTOR* mutations identified in other types of human cancer have also been shown to be activating mutations leading to increased rapamycin sensitivity ([@bb0010]). *mTOR* mutations have rarely been investigated in thyroid cancer. However, in a patient with ATC, an *mTOR* mutation was identified and shown to confer resistance to allosteric *mTOR* inhibition, although this *mTOR* mutation has been shown to be sensitive to *mTOR* kinase inhibitors ([@bb0040]). Therefore, finding *mTOR* mutations in a patient not only becomes an important factor in the selection of cancer treatment but might be a valuable and promising prognostic marker.

In this report, we found two previously reported SNPs but no other genetic variants. These results suggest that somatic mutations of the *mTOR* gene are rare in DTC and genetic alterations of *mTOR* gene may not play a significant role in the pathogenesis of this cancer. Genetic mutations in other genes in the *PIK3*/*AKT* pathway including *PIK3CA*, *PTEN*, and *AKT* have been described in thyroid cancer, mostly in PDTC. It has also been reported that other genetic deregulation of the genes of PI3K/Akt signaling pathway is common in PDTC ([@bb0020]) but not DTC wherein the majority of the MAPK pathway genes are commonly mutated ([@bb0045]). Furthermore, as the previously reported *mTOR* mutations were from patients with ATC, we considered the possibility that *mTOR* mutations might be limited to high grade PTC. However, our search for *mTOR* mutations in 21 such samples in the most frequently mutated exons yielded no mutations. We have analyzed a large number of previously reportedly mutated *mTOR* exons. However, it is also possible that *mTOR* mutations occur in the other non-analyzed exons of *mTOR* and may also occur in other ethnic groups. To the best of our knowledge, this is the first study that systematically analyzed a large number of *mTOR* exons for mutations in a relatively large sample of thyroid cancer using standard methods of PCR and Sanger sequencing.

Despite the low yield of mutations in this study, further studies from other ethnic backgrounds are warranted focusing on more advanced thyroid cancer types and analyzing all exons of *mTOR* in order to make definitive conclusions on the role of the *mTOR* mutations in thyroid cancer and its sub-types.

Declaration of interest {#s0025}
=======================

The authors have no conflict of interest to declare.

This work was supported by King Abdulaziz City for Science and Technology, Riyadh, Saudi Arabia (12-BIO2952-20).
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Primers used for PCR amplification of the *mTOR* gene.

  Exons   Sense                     (5′→ 3′)   Antisense
  ------- ------------------------- ---------- -------------------------
  1       GTGACCAGGGCCATAAGTAAAT               GACAGGTTGGGTGCCTTTAT
  2       CCACCACCACAGTTAGAGAATTA              CAGGGCTGCTGCTAGAATTA
  3       CCTCCCAAAGTGCTAGGATTAC               CCACCACACCATGCTAGATT
  4       TCCTGGTGTGTATGGCTCTAA                TTTGCTAGTGGTGGGAATGG
  5       TAGATGGGATGGGCCTGTAT                 CTTGCCTCGCTCACAGAAT
  6       TAGTTGCGTTTCGGGATTAGG                ACACCTGAGAGAGGAAGGATAA
  8       CCTAACCCTGACCTGGAGC                  TGGGCGTAAGCTCCGTGGA
  12      AATCTTCCCACTACGCTGATG                CAGGGAAACATTTGGACCTTTG
  16      TCTCGTACTGGCTCATTGAATC               CCATCGTCCCAGCAAAGT
  21      GCTGCGTGTCCTTAGATACTT                GAAAGATGGCCTGGGAACTTA
  25      AATTGGCCCTTGAAACTGATTG               AGATGCTACAGTATGAGCTTGTT
  29      AGCAGCACATTAGGAAAGAGAG               CTGAAGTGAGAACTCCGTGTG
  38      CCATTTCTGAGTGTCTCCTTGA               GCAGTGCTGGATGGTAGATAG
  42      CTGGTAGTCTCAAGCAGATGTT               TGGAGACACAGGAGGTACTATT
  46      GAGCTGAGGACCTCTGATGTA                CATGCCTGGCTCCCTAATTT
  50      AGATAGCACCACTGCCTTC                  GACCTTACATATACAATAC
  51      ATCGTTTGCCAACTCCTAG                  TTAACTACAGCCTTGGTAG
  52      TTGCTTTGGGTGGAGAGTTAG                CCAGTCTCAGGCAGTTCTTTAT
  55      CCTGTTGTATTGCTCCCATTCT               GTGCCAAAGCTCGTCACTAA

[^1]: Co-first authors.
